Celecoxib vs Naproxen for Migraine Pain

Celecoxib vs naproxen for migraine pain: similar short-term relief, different stomach and heart trade-offs, and when to ask a clinician.

In this guide
  1. Neither Pill Is the Default Migraine Winner
  2. Celecoxib vs Naproxen at a Glance
  3. How Each Drug Acts on Migraine Pain
  4. Why Noninferior Does Not Mean Heart Safe
  5. Which Situations Change the Lean
  6. When Repeated Rescue Use Needs a Wider Plan
  7. Bring a Risk Snapshot to Your Clinician

You're comparing two familiar anti-inflammatory names during or after an attack, often after someone told you to "take an NSAID" and left the choice hanging. Studies suggest celecoxib and naproxen can relieve acute migraine pain to a similar degree in the short term. Naproxen has stronger guideline support for treating an attack, and celecoxib has looked easier on the stomach in selected high-risk trials. That is a starting map, not a best-drug ranking and not a personal plan.

This article is for informational purposes and is not medical advice. Consult a healthcare provider for personalized guidance.

Neither Pill Is the Default Migraine Winner

Say the pain has already climbed, light feels harsh, and you're scrolling pharmacy names because the last visit ended with "use an anti-inflammatory if it helps." The useful split is this. For one treated attack, research indicates the two drugs can look alike on pain. For repeated NSAID days, stomach history, heart history, kidneys, and how often you rescue start to matter more than the brand on the bottle.

Migraine is not an ordinary headache. It is a neurological attack that can move through phases, and those phases are easy to mix up when you're exhausted.

Prodrome is the early warning stretch, sometimes hours before pain, with yawning, food cravings, neck stiffness, or mood change. Aura is a reversible neurological symptom, often visual, that some people get and many never do. Photophobia means light hurts or feels unbearable. Phonophobia means sound does the same. Postdrome is the drained recovery after the worst pain eases, when thinking still feels slow.

A pain score going down does not prove the medicine handled nausea, light sensitivity, sound sensitivity, aura, or that wiped-out recovery. Migraine also varies. Episodic and chronic patterns differ, and so do attacks with aura, vestibular symptoms, or rare forms such as hemiplegic migraine. Nothing here assumes your attacks match someone else's.

When the comparison should stop

Some symptoms are not a celecoxib vs naproxen decision. Get emergency care now, not a medicine debate, if you have any of these:

  • Sudden worst-ever headache: Pain that peaks in a way you've never felt.
  • Fever with a stiff neck: Especially if you also feel confused or very unwell.
  • New neurological changes: Weakness, trouble speaking, vision loss, or confusion that is new for you.
  • Headache after head injury: Even if the injury seemed minor at first.

Practical rule: If the attack is unlike your usual migraine, treat it as a medical emergency until a clinician says otherwise.

What follows is a snapshot table, then the evidence behind each row, then the situations that should change the conversation with a clinician or pharmacist. Arthritis-trial safety numbers are not a migraine dosing plan, and neither drug is a preventive.

Celecoxib vs Naproxen at a Glance

QuestionCelecoxibNaproxen
What it isPrescription COX-2-selective NSAID, brand CelebrexNonselective NSAID; naproxen and naproxen sodium, including OTC forms
Main actionPreferentially blocks COX-2Blocks COX-1 and COX-2
Role in migrainePossible acute pain option, not a preventive and not migraine-specificAcute pain option with stronger guideline support, not a preventive
Acute migraine evidenceSimilar pain relief in one open-label trial; 2025 guideline support is weakSimilar pain relief in that trial; 2025 guideline support is strong
Stomach signalFewer serious GI events in PRECISION, HR 0.71More serious GI events in PRECISION; more gastric pain in the migraine trial
Heart signal2.3% composite events in PRECISION; noninferior, not protective2.5% composite events; not shown safer for every person
Kidney signal0.7% renal events; difference not significant0.9% renal events; both can affect kidneys
Do not choose alone ifPrior ulcer or bleed, heart disease, kidney disease, pregnancy, blood thinners, or daily rescue useSame red-line situations; OTC access does not remove them

Celecoxib is a prescription COX-2-selective NSAID, often known by the brand Celebrex. Naproxen is a nonselective NSAID, sold as naproxen and as naproxen sodium, including over-the-counter products. OTC access does not make naproxen a casual daily migraine tool.

What the arthritis trial actually measured

In the large PRECISION trial published in the New England Journal of Medicine, moderate-dose celecoxib was noninferior to naproxen for cardiovascular death, nonfatal myocardial infarction, or stroke in arthritis patients with high cardiovascular risk. Event rates were 2.3% for celecoxib versus 2.5% for naproxen. Serious gastrointestinal events were fewer with celecoxib, with a hazard ratio of 0.71 (95% CI 0.54–0.93). Renal events were 0.7% versus 0.9% (HR 0.79; P=0.19), and that difference was not statistically significant.

A PubMed report of PRECISION gives the composite hazard ratio as 0.97 (95% CI, 0.83–1.12; p=0.64), which is how the trial met noninferiority. It did not prove either drug is heart-safe. A separate account of the same cardiovascular-safety trial places those composite events during a mean follow-up of 34.1 months in people treated for arthritis, not for a few migraine hours, as described in the New England Journal of Medicine report of follow-up.

On migraine pain itself, one open-label trial found similar short-term relief, with more gastric pain on naproxen sodium. That tolerability note is not a reason to ignore heart, kidney, or bleeding history.

These safety numbers come from chronic arthritis treatment, not occasional migraine use, and both drugs keep NSAID-class cardiovascular, gastrointestinal, and kidney risks.

Dose, treatment length, baseline heart disease, high blood pressure, kidney function, ulcer history, anticoagulants, and dehydration can change the practical choice. Celecoxib may offer a gastrointestinal advantage at the doses studied in arthritis care, but it is not "heart-safe," and naproxen is not automatically safer for every person. A short, early treatment of one attack is a different exposure from near-daily rescue. People with cardiovascular, kidney, gastrointestinal, or pregnancy-related risks need a clinician or pharmacist in that decision. Nothing in this table is a dose to copy.

How Each Drug Acts on Migraine Pain

Pain signals in an attack are not only "inflammation in the head." Prostaglandins are chemical signals that amplify pain and inflammation. Both drugs turn that volume down by blocking cyclooxygenase enzymes, usually shortened to COX. They don't block the same set.

An infographic showing how Celecoxib and Naproxen work to relieve migraine pain by inhibiting COX-1 and COX-2 enzymes.

Celecoxib is COX-2-preferential. It mainly targets the enzyme tied to pain and inflammation. Naproxen is nonselective, so it also inhibits COX-1 pathways tied to stomach lining protection and to platelets. That extra COX-1 block is a practical reason gastric discomfort can differ. Selectivity does not make celecoxib harmless for the heart, blood pressure, or kidneys. Both remain NSAIDs.

What one migraine trial can and can't say

For acute migraine, a randomized open-label trial indexed on PubMed found celecoxib and naproxen sodium similarly effective for relieving pain. Gastric pain occurred significantly more often with naproxen sodium than with celecoxib (p=0.029). Similar short-term pain relief is not identical tolerability.

Open-label means participants and clinicians knew the assigned drug, so expectation can influence what people report. The result is not a personal treatment assignment, and it does not crown a winner.

The trial's pain result is not proof that either medicine treats nausea, photophobia, phonophobia, aura, or postdrome. If those features dominate your attacks, an anti-inflammatory alone may leave a large part of the migraine untouched. Bring that gap to a clinician instead of copying a study arm.

Where these drugs sit among other options

Keep the buckets separate so an NSAID comparison doesn't swallow the rest of care.

  • Lifestyle approaches: Sleep timing, hydration, and regular meals can change attack load for some people. They don't replace acute treatment when pain is already building.
  • Over-the-counter options: Naproxen sodium is one of them. Access at a pharmacy counter is not the same as a safety clearance.
  • Other prescription acute classes: Triptans and gepants are migraine-specific tools. They are a different conversation from swapping one NSAID for another.
  • Preventives and emerging research: Medicines and devices aimed at fewer attacks sit outside a single-rescue comparison. Research in this area keeps moving, and it still needs a clinician who knows your history.

A 2025 evidence-based migraine guideline strongly supported naproxen for acute treatment and gave oral celecoxib only a weak recommendation. That signals a thinner evidence base for celecoxib, not proof that celecoxib fails.

Onset and how long relief lasts

Readers often want a faster pill and a longer one. The open-label migraine trial and that guideline rating cover pain relief and evidence strength, not minutes to relief or hours of effect. This evidence does not name a faster or longer-lasting drug. Attack length, formulation, and your own history still decide duration.

Keep the measured tolerability point beside that limit. More gastric pain with naproxen sodium (p=0.029) is a stomach finding, not a speed ranking. If stomach upset has stopped you from finishing a dose before, that belongs in the visit, next to the pain result, not as a reason to self-rank the drugs.

Why Noninferior Does Not Mean Heart Safe

The consumer shortcut is tidy and wrong. Naproxen is not automatically the heart-safe NSAID, and celecoxib is not automatically the dangerous one. Group results that look close can still be a poor fit for one person.

An infographic explaining that noninferiority study results between celecoxib and naproxen do not equate to heart safety.

Noninferiority means the trial did not find celecoxib worse than naproxen beyond a preset margin. It is not proof that either drug removes cardiovascular risk. PRECISION enrolled people with osteoarthritis or rheumatoid arthritis who already had cardiovascular risk factors. It did not enroll people using a medicine for a few migraine hours. You can't treat that chronic comparison as a migraine dosing plan.

What still changes your risk

Even when average event rates sit near each other, individual risk is not an average.

  • Existing cardiovascular disease: Prior heart attack, stroke, or known coronary disease raises the stakes of any NSAID.
  • High blood pressure: NSAIDs can push readings up, including in people who already take blood-pressure medicine.
  • Smoking, diabetes, and age: Each adds background risk the trial average can't personalize.
  • Length of exposure: A single treated attack is not the same load as weeks of regular use.

NSAIDs as a class may raise blood pressure, promote fluid retention, and strain kidneys. That strain is easier to miss when you're dehydrated, ill, on a diuretic, or already living with kidney disease. Vomiting during migraine is a common way people lose fluid without thinking of their kidneys. The renal comparison in PRECISION was not a clear win for either drug.

Celecoxib's COX-2 selectivity does not supply the platelet effect people associate with aspirin. It is not a substitute blood thinner, and it is not a reason to skip a prescribed heart medicine. Naproxen's COX-1 effect on platelets is also not a license to treat it as protection.

Celecoxib was not worse than naproxen on the studied heart outcome, and naproxen was not shown to protect you.

If you want a short walk-through of why "noninferior" gets misread as "safe," this explainer is a useful companion to the trial language.

Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or NaproxenRadcliffe Cardiology · plays from YouTube

Anyone with heart disease, hypertension, or kidney disease should talk with a clinician or pharmacist before either NSAID, including an over-the-counter naproxen product. The label on the shelf doesn't do that review for you.

Which Situations Change the Lean

The celecoxib vs naproxen question gets clearer when you start from your situation instead of from a heart-safety ranking.

An occasional attack without major history

If attacks are occasional and you don't have an ulcer history, heart disease, kidney disease, pregnancy, or blood thinners, naproxen's stronger acute-migraine evidence may matter more for a single rescue. Stomach tolerability can still justify asking about celecoxib. Asking is the action. Picking alone because a friend tolerated one of them is not.

A past bleed changes the safety talk

A prior upper-gastrointestinal bleed is not a home switch. In the CONCERN trial in The Lancet30981-9/fulltext), people with previous upper-GI bleeding, cardiothrombotic disease, and arthritis, all of whom received a proton-pump inhibitor, had less recurrent bleeding on celecoxib plus that acid-reducing medicine than on naproxen plus the same kind of protection. Over 18 months, recurrent upper-GI bleeding occurred in 5.6% with celecoxib versus 12.3% with naproxen. The crude hazard ratio was 0.44 (95% CI, 0.23–0.82; p=0.010), an absolute reduction of about 6.7 percentage points.

That is a safety difference in a high-risk arthritis population, many of whom were also on low-dose aspirin. It does not show celecoxib works better for migraine pain, and it does not make celecoxib risk-free. A past ulcer or bleed means clinician review before either drug is restarted.

Other stacks that should pause you

Bleeding risk adds up. Anticoagulants, antiplatelet drugs including low-dose aspirin, steroids, and a second NSAID all push in the same direction. Don't stack ibuprofen, naproxen, and celecoxib. If one anti-inflammatory is already in your system, another one is not a "different" medicine for this purpose.

Late pregnancy, and attempts to conceive, need obstetric guidance. NSAID risks are timing-specific, and a package comparison can't settle them. Dehydration from vomiting, a common migraine feature, flags kidney vulnerability for both drugs, especially if you also take a diuretic.

A wider look at acute and preventive categories sits in this guide to migraine medication options. Use it to name the class you want to discuss, not to choose a product in the aisle.

Your situationWhat the evidence leans towardWhat to do next
Occasional attack, no major GI, heart, or kidney historyNaproxen has stronger acute-migraine evidence; tolerability can still differAsk which acute option fits your history
Prior ulcer or upper-GI bleedCelecoxib plus a PPI had less recurrent bleeding than naproxen plus a PPI in CONCERN: 5.6% versus 12.3% over 18 months, HR 0.44Do not restart either drug without clinician review
Cardiovascular disease or multiple heart risksNeither drug is heart-safe; PRECISION showed noninferiority only, 2.3% versus 2.5%Review blood pressure, heart history, and alternatives
Kidney disease, dehydration, or diureticsBoth NSAIDs can worsen kidney function; PRECISION renal events 0.7% versus 0.9%, not significantSeek advice before use, especially while vomiting
Aspirin, anticoagulant, steroid, or more than one NSAIDBleeding risk stacksAsk a pharmacist or clinician; do not combine NSAIDs
Pregnancy or trying to conceiveNSAID risk depends on timing and personal historyUse obstetric guidance, not a package comparison

Bring the matching row to the visit in your own words. "I had a bleed in 2019 and I'm on aspirin" is more useful than "which pill is safer for the heart?" No row here names a dose or a universally best prescription.

When Repeated Rescue Use Needs a Wider Plan

Frequent attacks are where stomach-comfort comparisons stop being the main question. A 2025 evidence-based migraine guideline strongly supported naproxen for acute treatment and gave oral celecoxib only a weak recommendation. That means a thinner evidence base for celecoxib, not proof that it fails. Swapping one NSAID for the other is still not a long-term plan.

Medication-overuse headache is a loop. More attack days lead to more acute dosing. More acute dosing can raise headache burden and, with NSAIDs, add stomach, blood-pressure, kidney, and cardiovascular exposure. The fix is not a tougher mindset. It is a wider plan than rotating anti-inflammatories.

An infographic list outlining six steps for managing frequent migraine rescue medication use with a healthcare plan.

Four actions, and no doses to copy

  1. Log each acute-medicine day. Write the drug name and whether the episode was migraine rather than an ordinary headache. A month of those marks shows rescue creep faster than memory does.
  2. Don't combine NSAIDs. Celecoxib plus naproxen, or either one plus ibuprofen, stacks gastrointestinal risk without giving you a migraine-specific plan.
  3. Reassess when rescue days are rising. That visit is about frequency and disability, not only about which anti-inflammatory felt kinder to your stomach. More on how the loop works is in this explanation of medication-overuse headache.
  4. Ask about a different class. Migraine-specific acute options, such as triptans or gepants, or a preventive, belong in that conversation. Rotating celecoxib and naproxen keeps you inside the same drug family.

Early treatment is not a preemptive pill

Treating an attack early, once pain or prodrome has started, is different from taking a pill because a trigger might occur. Weather, skipped meals, and short sleep are common triggers some people identify. They are not a schedule for dosing "just in case." Routine preemptive NSAID use is how occasional rescue becomes near-daily exposure.

Logging those medicine days makes the pattern visible before a visit, and it does not replace care.

If attacks cluster for several days, note the cluster as one stretch of migraine days rather than as proof you need a stronger anti-inflammatory. The signal to widen the plan is repeated rescue, worsening attacks, or reliance on an NSAID most weeks. A clinician can match that pattern to migraine-specific acute care or prevention. You don't have to decide the class alone in the pharmacy.

Bring a Risk Snapshot to Your Clinician

The decision you can make today is what to carry into the visit, not which dose to start. A one-page snapshot beats a foggy memory of "I take something for pain."

  1. Every current medicine name, including over-the-counter naproxen or ibuprofen, plus supplements you take most days.
  2. Ulcer or bleeding history, including a bleed that was years ago and "healed."
  3. Heart disease and blood pressure, including home readings if you have them.
  4. Kidney problems and recent vomiting or dehydration, especially if attacks come with hours of nausea.
  5. Pregnancy or plans to conceive, so timing-specific NSAID risks get obstetric input.
  6. Aspirin, anticoagulants, or steroids, because bleeding risk stacks even when each drug felt fine alone.
  7. How many days a month an acute medicine is used, counted from a log rather than a guess.
  8. Which features remain after pain eases, such as nausea, photophobia, or postdrome fatigue. Those leftovers tell the clinician an NSAID may be only part of the attack.

A sudden worst-ever headache, fever with a stiff neck, new neurological changes, or headache after head injury needs emergency care, not a drug comparison.

Where to read further, and what a log changes

Trial publications are the right depth if you want the original numbers. For plain-language background, major references from Mayo Clinic and the NHS, plus the American Migraine Foundation and the International Headache Society, are the kinds of sources worth trusting over forum threads. Our guides stay general on purpose. Relief has no medical advisers yet, so its guides stay general, make no medical recommendations and list their sources.

One next step is enough. Log attacks, suspected triggers, and the medicine name so the visit starts from a record. A simple medication tracker chart can keep those days visible without turning the log into a diagnosis. The app supports tracking and awareness. It does not replace a pharmacist, a clinician, or emergency care.

This article is informational and is not medical advice.

This guide is general information, not medical advice, and it isn’t a diagnosis. Talk to your doctor about your own headaches.